ThirtyFiveBio
PrivateLast Round
VC Round
Apr 15, 2025
Total Funding Raised
$21.44M
Company Overview
ThirtyFiveBio operates in Healthcare & Life Sciences and is based in Abingdon. Its latest recorded funding round was a VC Round in April 2025.
ThirtyFiveBio is a biotechnology company developing first-in-class small-molecule inhibitors of G protein-coupled receptor 35 (GPR35) to treat severe gastrointestinal diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ThirtyFiveBio Comparables
Compare ThirtyFiveBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nxera Pharma | 73% | |
| Bristol Myers Squibb | 71% | |
| N-Zyme Biomedical | 70% |
For institutional investors. Book with your work email.
ThirtyFiveBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Apr 15, 2025 | ||||
| Grant | Jul 2, 2024 | ||||
| Grant | Sep 13, 2023 |
For institutional investors. Book with your work email.
ThirtyFiveBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| AbbVie Ventures | VC Round |
| Innovate UK | Grant |
| Canaan Partners | Seed, VC Round |
| Mayewell Capital | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 15, 2025
Raised $3.56M led by Canaan Partners
For institutional investors. Book with your work email.
ThirtyFiveBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ThirtyFiveBio's valuation, stock price, and market status.
Is ThirtyFiveBio a public or private company?
ThirtyFiveBio is a private company.
What is the current stock price of ThirtyFiveBio?
ThirtyFiveBio is a private company, so its shares have no public market price. Caplight tracks ThirtyFiveBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ThirtyFiveBio worth (valuation)?
Valuation information for ThirtyFiveBio is not publicly available.
Can I buy ThirtyFiveBio stock?
ThirtyFiveBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ThirtyFiveBio's last funding round?
ThirtyFiveBio's most recent funding round was VC Round on April 15, 2025.
Who are the main investors in ThirtyFiveBio?
Key investors in ThirtyFiveBio include Innovate UK, AbbVie Ventures, Innovate UK, Canaan Partners, Mayewell Capital.
Will ThirtyFiveBio IPO soon?
No public IPO plans have been announced for ThirtyFiveBio.
How can I track ThirtyFiveBio secondary market activity?
Caplight tracks bids, offers, and trades in ThirtyFiveBio's shares on secondary markets.